{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:51:49Z","timestamp":1781607109485,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T00:00:00Z","timestamp":1429142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s12020-015-0601-2","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T03:39:03Z","timestamp":1429069143000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical management of critically ill patients with Cushing\u2019s disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide"],"prefix":"10.1007","volume":"52","author":[{"given":"S.","family":"Cannavo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ferrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Priola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,16]]},"reference":[{"key":"601_CR1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/cen.12442","volume":"81","author":"HR Kakade","year":"2014","unstructured":"H.R. Kakade, R. Kasaliwal, K.S. Khadilkar, S. Jadhav, A. Bukan, S. Khare, S.R. Budyal, A. Goel, A.R. Lila, T. Bandgar, N.S. Shah, Clinical, biochemical and imaging characteristics of Cushing\u2019s macroadenomas and their long-term treatment outcome. Clin. Endocrinol. 81, 336\u2013342 (2014)","journal-title":"Clin. Endocrinol."},{"key":"601_CR2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.0.1490195","volume":"149","author":"S Cannavo","year":"2003","unstructured":"S. Cannavo, B. Almoto, C. Dall\u2019Asta, S. Corsello, R.M. Lovicum, E. De Menis, F. Trimarchi, B. Ambrosi, Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur. J. Endocrinol. 149, 195\u2013200 (2003)","journal-title":"Eur. J. Endocrinol."},{"key":"601_CR3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1210\/jc.2012-3200","volume":"98","author":"X Bertagna","year":"2013","unstructured":"X. Bertagna, L. Guignat, Approach to the Cushing\u2019s disease patient with persistent\/recurrent hypercortisolism after pituitary surgery. J. Clin. Endocrinol. Metab. 98, 1307\u20131318 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"601_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12020-013-0129-2","volume":"47","author":"A Colao","year":"2014","unstructured":"A. Colao, M. Boscaro, D. Ferone, F.F. Casanueva, Managing Cushing\u2019s disease: the state of the art. Endocrine 47, 9\u201320 (2014)","journal-title":"Endocrine"},{"key":"601_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1210\/jc.2012-3126","volume":"98","author":"RA Feelders","year":"2013","unstructured":"R.A. Feelders, L.J. Hofland, Medical treatment of Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 98, 425\u2013438 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"601_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12020-013-0098-5","volume":"46","author":"D Ferone","year":"2014","unstructured":"D. Ferone, C. Pivonello, G. Vitale, M.C. Zatelli, A. Colao, R. Pivonello, Molecular basis of pharmacological therapy in Cushing\u2019s disease. Endocrine 46, 181\u2013198 (2014)","journal-title":"Endocrine"},{"key":"601_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94, 115\u2013122 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"601_CR8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 Study Group: a 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366, 914\u2013924 (2012)","journal-title":"N. Engl. J. Med."},{"key":"601_CR9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11102-012-0427-3","volume":"15","author":"I Shimon","year":"2012","unstructured":"I. Shimon, L. Rot, E. Inbar, Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15, 608\u2013613 (2012)","journal-title":"Pituitary"},{"key":"601_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF03345431","volume":"35","author":"G Arnaldi","year":"2012","unstructured":"G. Arnaldi, T. Mancini, G. Tirabassi, L. Trementino, M. Boscaro, Advances in the epidemiology, pathogenesis, and management of Cushing\u2019s syndrome complications. J. Endocrinol. Invest. 35, 434\u2013448 (2012)","journal-title":"J. Endocrinol. Invest."},{"issue":"Suppl 1","key":"601_CR11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000314317","volume":"92","author":"AM Pereira","year":"2010","unstructured":"A.M. Pereira, J. Tiemensma, J.A. Romijn, Neuropsychiatric disorders in Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1), 65\u201370 (2010)","journal-title":"Neuroendocrinology"},{"key":"601_CR12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40618-014-0126-1","volume":"37","author":"L Trementino","year":"2014","unstructured":"L. Trementino, L. Ceccoli, C. Concettoni, G. Marcelli, G. Michetti, M. Boscaro, G. Arnaldi, Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX\u00ae algorithm useful? J. Endocrinol. Invest. 37, 957\u2013965 (2014)","journal-title":"J. Endocrinol. Invest."},{"key":"601_CR13","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenick\u00fd","year":"2011","unstructured":"P. Kamenick\u00fd, C. Droumaguet, S. Salenave, A. Blanchard, C. Jublanc, J.F. Gautier, S. Brailly-Tabard, S. Leboulleux, M. Schlumberger, E. Baudin, P. Chanson, J. Young, Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 96, 2796\u20132804 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"601_CR14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","volume":"167","author":"VA Preda","year":"2012","unstructured":"V.A. Preda, J. Sen, N. Karavitaki, A.B. Grossman, Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review. Eur. J. Endocrinol. 167, 137\u2013143 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"601_CR15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"F. Castinetti, M. Fassnacht, S. Johanssen, M. Terzolo, P. Bouchard, P. Chanson, C. Do Cao, I. Morange, A. Pic\u00f3, S. Ouzounian, J. Young, S. Hahner, T. Brue, B. Allolio, B. Conte-Devolx, Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur. J. Endocrinol. 160, 1003\u20131010 (2009)","journal-title":"Eur. J. Endocrinol."},{"key":"601_CR16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1100\/tsw.2008.20","volume":"8","author":"S Mondello","year":"2008","unstructured":"S. Mondello, V. Fodale, S. Cannav\u00f2, C. Aloisi, B. Almoto, M. Buemi, L.B. Santamaria, Hypophosphatemia as unusual cause of\u00a0ARDS\u00a0in Cushing\u2019s syndrome secondary to ectopic CRH production. A case report. ScientificWorldJournal. 8, 138\u2013144 (2008)","journal-title":"ScientificWorldJournal."},{"key":"601_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","volume":"172","author":"JB Corcuff","year":"2015","unstructured":"J.B. Corcuff, J. Young, P. Masquefa-Giraud, P. Chanson, E. Baudin, A. Tabarin, Rapid control of intense neoplastic hypercortisolism with metyrapone and ketoconazole. Eur. J. Endocrinol. 172, 473\u2013481 (2015)","journal-title":"Eur. J. Endocrinol."},{"key":"601_CR18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-014-1508-0","volume":"119","author":"A Ayala","year":"2014","unstructured":"A. Ayala, A.J. Manzano, Detection of recurrent Cushing\u2019s disease: proposal for standardized patient monitoring following transsphenoidal surgery. J. Neurooncol. 119, 235\u2013242 (2014)","journal-title":"J. Neurooncol."},{"key":"601_CR19","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"R.A. Feelders, C. de Bruin, A.M. Pereira, J.A. Romijn, R.T. Netea-Maier, A.R. Hermus, P.M. Zelissen, R. van Heerebeek, F.H. de Jong, A.J. van der Lely, W.W. de Herder, L.J. Hofland, S.W. Lamberts, Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N. Engl. J. Med. 362, 1846\u20131848 (2010)","journal-title":"N. Engl. J. Med."},{"key":"601_CR20","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin dependent Cushing\u2019s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93, 2454\u20132462 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"601_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0746","volume":"167","author":"VA Preda","year":"2012","unstructured":"V.A. Preda, J. Sen, N. Karavitaki, A.B. Grossman, Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review. Eur. J. Endocrinol. 167, 137\u2013143 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"601_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12020-012-9846-1","volume":"44","author":"JD Carmichael","year":"2013","unstructured":"J.D. Carmichael, M. Fleseriu, Mifepristone: is there a place in the treatment of Cushing\u2019s disease? Endocrine 44, 20\u201332 (2013)","journal-title":"Endocrine"},{"key":"601_CR23","author":"L Trementino","year":"2014","unstructured":"L. Trementino, M. Zilio, G. Marcelli, G. Michetti, M. Barbot, F. Ceccato, M. Boscaro, C. Scaroni, G. Arnaldi, The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing\u2019s disease: findings from a pilot study. Endocrine (2014). doi: 10.1007\/s12020-014-0499-0","journal-title":"Endocrine"},{"key":"601_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S29125","volume":"6","author":"G Golor","year":"2012","unstructured":"G. Golor, K. Hu, M. Ruffin, A. Buchelt, E. Bouillaud, Y. Wang, M. Maldonado, A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug. Des. Devel. Ther. 6, 71\u201379 (2012)","journal-title":"Drug. Des. Devel. Ther."},{"key":"601_CR25","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446\u20133453 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"601_CR26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"A. Colao, C. De Block, M.S. Gaztambide, S. Kumar, J. Seufert, F.F. Casanueva, Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17, 180\u2013186 (2014)","journal-title":"Pituitary"},{"key":"601_CR27","author":"C Simeoli","year":"2015","unstructured":"C. Simeoli, R.S. Auriemma, F. Tortora, M. De Leo, D. Iacuaniello, A. Cozzolino, M.C. De Martino, C. Pivonello, C.G. Mainolfi, R. Rossi,\u00a0S. Cirillo,\u00a0A. Colao,\u00a0R. Pivonello, The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine. (2015). doi: 10.1007\/s12020-015-0557-2","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-015-0601-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0601-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T09:18:53Z","timestamp":1566551933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-015-0601-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,16]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1007\/s12020-015-0601-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,16]]}}}